Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Medicare Contractors Provide Guidance for Use of JA, JB Modifiers

From the College  |  June 7, 2021

As of April 2021, Medicare requires the use of the JA or JB modifier when billing for drugs that have one Healthcare Common Procedure Coding System (HCPCS) Level II (J or Q) code but multiple routes of administration. In response to numerous inquiries from ACR members, the Medicare Administrative Contractors (MACs) have provided the following guidance on billing with the JA and JB modifiers.

Drugs that require a JA or JB modifier will be marked with an asterisk (*) on the Usually Self-Administered Drug (USAD) List. Intravenous infusion of the drug must be billed with the JA modifier and subcutaneous injection of the drug with the JB modifier. Claims billed with the JA modifier are not part of the SAD exclusion. The MAC will process claims with the JA modifier applying the policy that, not only is the drug medically reasonable and necessary, but also that the route of administration is medically reasonable and necessary.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Claims for drugs marked with an asterisk (*) billed without a JA or JB modifier will be denied. One of the following denial messages will be received for Part B:

  • CARC 16 – Claim/service lacks information or has submission/billing error(s); OR
  • RARC N823 and N822 – Missing procedure modifier(s).

If a claim is denied, for Part A, providers can create an adjustment and resubmit their claim. For Part B, providers can resubmit their claim or request a re-opening.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

For specific questions regarding billing or denials, reach out to your MAC using the following contact numbers:

  • CGS customer service: 866-276-9558
  • NGS provider contact center
    • In Connecticut, Maine, Massachusetts, New Hampshire, New York, Rhode Island or Vermont: 866-837-0241
    • In Illinois, Minnesota or Wisconsin: 866-234-7340
  • Noridian Healthcare Solutions provider contact center
    • Region JE: 855-609-9960
    • Region JF: 877-908-8431
  • Palmetto customer service
    • Region JJ: 877-567-7271
    • Region JB: 855-696-0705
  • WPS customer service: 866-518-3285

For assistance working with the Medicare contractor for your region, or for help with any other insurance issues, contact ACR practice advocacy staff at [email protected].

Share: 

Filed under:Billing/Coding Tagged with:BillingModifierself-administration

Related Articles

    New HCPCS Modifiers Replace -59 on January 1, 2015

    December 1, 2014

    Referred to as -X modifiers, they are designed to define specific subsets of -59 modifier

    Coding Corner Answer: A Quiz on Modifiers

    February 18, 2019

    Take the challenge. 1. A—Modifier -25 is defined as a significant, separately identifiable evaluation and management (E/M) service by the same physician or other qualified healthcare professional on the same day of the procedure or other service. It is to be placed on the E/M visit only because it attests to the payer there is…

    Key Facts on Billing Drug Wastage

    January 24, 2023

    The ACR has compiled guidelines and tips on how to use the JW modifier and correctly bill Medicare for discarded drugs and biologicals. This modifier can be applied only to unused amounts from a single-dose vial or package.

    Practice Page: Is In-house or Outsourced Medical Billing Right for Your Physician Practice?

    February 1, 2014

    What to consider when deciding whether to delegate claims billing in-house or to contract with an outside company

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences